Articles with public access mandates - Lingzhi HongLearn more
Available somewhere: 19
Structure-based classification predicts drug response in EGFR-mutant NSCLC
JP Robichaux, X Le, RSK Vijayan, JK Hicks, S Heeke, YY Elamin, HY Lin, ...
Nature 597 (7878), 732-737, 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
MV Negrao, F Skoulidis, M Montesion, K Schulze, I Bara, V Shen, H Xu, ...
Journal for immunotherapy of cancer 9 (8), 2021
Mandates: US National Institutes of Health, Cancer Prevention Research Institute of …
Programmed death-ligand 1 heterogeneity and its impact on benefit from immune checkpoint inhibitors in NSCLC
L Hong, MV Negrao, SS Dibaj, R Chen, A Reuben, JM Bohac, X Liu, ...
Journal of Thoracic Oncology 15 (9), 1449-1459, 2020
Mandates: Cancer Prevention Research Institute of Texas, USA
The prognostic and therapeutic role of genomic subtyping by sequencing tumor or cell-free DNA in pulmonary large-cell neuroendocrine carcinoma
M Zhuo, Y Guan, X Yang, L Hong, Y Wang, Z Li, R Chen, HA Abbas, ...
Clinical Cancer Research 26 (4), 892-901, 2020
Mandates: US National Institutes of Health, National Natural Science Foundation of …
Current and future treatment options for MET exon 14 skipping alterations in non-small cell lung cancer
L Hong, J Zhang, JV Heymach, X Le
Therapeutic Advances in Medical Oncology 13, 1758835921992976, 2021
Mandates: US National Institutes of Health
Frequent KIT mutations in human gastrointestinal stromal tumors
Z Xu, X Huo, C Tang, H Ye, V Nandakumar, F Lou, D Zhang, S Jiang, ...
Scientific reports 4 (1), 5907, 2014
Mandates: US National Institutes of Health, National Natural Science Foundation of China
Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer
L Hong, M Aminu, S Li, X Lu, M Petranovic, MB Saad, P Chen, K Qin, ...
Nature communications 14 (1), 695, 2023
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study
MB Saad, L Hong, M Aminu, NI Vokes, P Chen, M Salehjahromi, K Qin, ...
The Lancet Digital Health 5 (7), e404-e420, 2023
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Genetic mutation analysis of human gastric adenocarcinomas using ion torrent sequencing platform
Z Xu, X Huo, H Ye, C Tang, V Nandakumar, F Lou, D Zhang, H Dong, ...
PloS one 9 (7), e100442, 2014
Mandates: US National Institutes of Health, National Natural Science Foundation of China
MET amplification as a resistance driver to TKI therapies in lung cancer: clinical challenges and opportunities
K Qin, L Hong, J Zhang, X Le
Cancers 15 (3), 612, 2023
Mandates: V Foundation, USA, Damon Runyon Cancer Research Foundation, Lung Cancer …
Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping
X Le, L Hong, C Hensel, R Chen, H Kemp, N Coleman, CA Ciunci, SV Liu, ...
JCO Precision Oncology 5, 1802-1812, 2021
Mandates: US National Institutes of Health
Concurrent use of aspirin with osimertinib is associated with improved survival in advanced EGFR-mutant non-small cell lung cancer
X Liu, L Hong, M Nilsson, SM Hubert, S Wu, W Rinsurongkawong, J Lewis, ...
Lung Cancer 149, 33-40, 2020
Mandates: US National Institutes of Health
HRAS Mutations Define a Distinct Subgroup in Head and Neck Squamous Cell Carcinoma
N Coleman, KL Marcelo, JF Hopkins, NI Khan, R Du, L Hong, E Park, ...
JCO Precision Oncology 7, e2200211, 2023
Mandates: US National Institutes of Health
Hint1 expression inhibits proliferation and promotes radiosensitivity of human SGC7901 gastric cancer cells
X Wei, J Zhou, L Hong, Z Xu, H Zhao, X Wu, J Chen
Oncology letters 16 (2), 2135-2142, 2018
Mandates: National Natural Science Foundation of China
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma
L Hong, WE Lewis, M Nilsson, S Patel, S Varghese, MJ Rivera, RR Du, ...
Cancers 14 (14), 3473, 2022
Mandates: US National Institutes of Health, Damon Runyon Cancer Research Foundation
Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma
Z Xu, C Cao, H Xia, S Shi, L Hong, X Wei, D Gu, J Bian, Z Liu, W Huang, ...
Frontiers of Medicine 10, 52-60, 2016
Mandates: National Natural Science Foundation of China
Habitat imaging biomarkers for diagnosis and prognosis in cancer patients infected with COVID-19
M Aminu, D Yadav, L Hong, E Young, P Edelkamp Jr, M Saad, ...
Cancers 15 (1), 275, 2022
Mandates: US National Institutes of Health
Brief Report: Clinical Response, Toxicity, and Resistance Mechanisms to Osimertinib Plus MET Inhibitors in Patients With EGFR-Mutant MET-Amplified NSCLC
K Wang, R Du, S Roy-Chowdhuri, ZT Li, L Hong, N Vokes, YY Elamin, ...
JTO Clinical and Research Reports 4 (8), 100533, 2023
Mandates: V Foundation, USA
Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma
R Chen, J Li, J Fujimoto, L Hong, X Hu, K Quek, M Tang, A Mitra, ...
Journal of Experimental & Clinical Cancer Research 41 (1), 172, 2022
Mandates: US Department of Defense, US National Institutes of Health, Cancer …
Publication and funding information is determined automatically by a computer program